Brazilian Regulator Consults On Improving Rules For Registering Biosimilars
Executive Summary
ANVISA, Brazil’s medicines regulator, is asking for feedback on the regulatory pathway for biosimilars.
You may also be interested in...
UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.
Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.